Delivery Order SPE2DB20D3103-SPE2DB25FM6Z1

Award Date 2/13/25
Potential Completion Date 2/14/25
Potential Value $9.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,554.79 firm fixed-price delivery order contract is for the supply of 4,567,282,823 units of 30 mg Oseltamivir Phosphate capsules. The contract has a ceiling value of $3,554.79 and runs through February 18, 2025. This award is part of AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,987.17 firm fixed-price delivery order is for the purchase of 4,567,104,683 units of Oseltamivir Phosphate 75mg capsules, a medication used to treat influenza. The contract has an ultimate completion date of January 31, 2025 and was awarded on January 30, 2025. Amerisourcebergen holds a $999,999,999 Indefinite...
This federal contract award, valued at $1,425.01, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) for the supply of 4,564,007,468 units of Oseltamivir Phosphate 75mg capsules. The contract has an ultimate completion date of March 20, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen, a for-profit...
This federal contract award, valued at $12,975.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,559,450,627 units of Oseltamivir Phosphate 75 mg capsules, which are used to treat influenza. The contract has an ultimate completion date of December 27, 2022 and is structured as a firm fixed-price delivery order. There is no set-aside designation, indicating the contract was awarded through...
This federal contract award, valued at $1,317.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of 4,562,181,703 units of Oseltamivir Phosphate 75 mg capsules, with an ultimate completion date of September 15, 2023. The contract is not designated with a set-aside requirement, indicating open competition. It is part of a larger Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,732.12 firm fixed-price delivery order is for the supply of 4,558,866,552 units of the drug Oseltamivir Phosphate 30 mg capsules, with an ultimate completion date of October 25, 2022. This award is a part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,545.37, is for the delivery of 4,566,476,996 units of the drug Oseltamivir Phosphate 75mg capsules. The contract is a Delivery Order with a Firm Fixed Price pricing type and has a completion date of November 19, 2024. The contract is not designated as a set-aside. AmerisourceBergen has a...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order under the Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,126.99 firm fixed-price contract is for the delivery of 4,566,703,864 units of Oseltamivir Phosphate 75 mg capsules, a medication used for the treatment of influenza. The contract has a performance period through December 13, 2024 and does not...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,035.78 firm fixed-price delivery order contract is for the supply of 4,562,562,995 units of Oseltamivir Phosphate 75 mg capsules. The contract has an ultimate completion date of October 24, 2023 and was awarded on October 23, 2023. This appears to be a task order under a larger Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,041.06 firm fixed-price delivery order is for the supply of 4567341626 Oseltamivir Phosphate 75 mg capsules. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FM6Z1
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,881.50 delivery order contract is for the provision of 4,567,267,230 units of the drug Oseltamivir Phosphate 75 mg capsules. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a firm fixed price pricing type and a completion date of February 14, 2025. The contract was not designated with any set-aside requirements, indicating open competition.

Generated 5/22/25, 8:04 PM